Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females of age ≥ 18 years.~2. Individuals who had given written consent.~3. Individuals in good health and available for all the visits scheduled in the study.~Exclusion Criteria:~1. Pregnancy or unwillingness to practice acceptable contraception.~2. A history of Rabies vaccination.~3. History of allergy to egg protein.~4. Known hypersensitivity to neomycin, tetracycline, amphotericin-B or any other vaccine component.~5. A significant acute or chronic infectious disease or use of antibiotics that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment.~6. Body temperature ≥38.0°C (≥ 100.4°F) within 3 days of study vaccination.~7. Treatment with an anti-malarial drug, up to two months prior to the study.~8. Individuals who received any other vaccines within 28 days prior to enrollment.~9. Subjects who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks.~10. Any planned surgery during the study period.~11. Subjects who have cancer disorders excluding nonmelanotic skin cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A-Zagreb (Type: ACTIVE_COMPARATOR): Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
- Group B-Essen (Type: ACTIVE_COMPARATOR): Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)

Based on this trial design, predict the completion outcome and termination type (if applicable).